

NeuroHelp

<https://www.neuro-help.com/>

CEO name----Nadav Karni-----*

Investment Rational

NeuroHelp is revolutionizing epilepsy care with Epiness™, a wearable EEG system for real-time seizure detection and prediction up to four hours in advance. With a significant unmet need, strong early clinical collaborations, and an experienced team in AI and neurotech, NeuroHelp is poised for major impact in tele-neurology.

Business Strategy

We aim to first target epilepsy patients through home-use and clinical monitoring markets. Near-term revenue will come from a device and subscription model. Long-term, we will expand to broader neurological disorders, offering remote monitoring tools to clinics, hospitals, and telemedicine platforms globally.

Core Technology

Epiness™ combines advanced EEG acquisition, physiological sensing, and AI-driven algorithms to predict and detect seizures with high sensitivity and very low false-alarm rates. Its unique value lies in offering early warnings and continuous remote neurological monitoring, significantly improving patient safety and healthcare efficiency.

Product Profile/Pipeline

Our first product is a wearable EEG-based seizure detection and prediction device, entering clinical trials in May 2025. In parallel, we are developing a software-only, hardware-agnostic seizure monitoring platform for hospitals. Future pipeline targets include sleep management and remote neurology solutions.

What's Next?

We will launch exploratory clinical trials in Israel, followed by FDA-directed studies in the U.S. Organizational growth includes strengthening clinical, regulatory, and AI teams. Financially, we are raising funds to complete clinical studies, secure regulatory clearance, and accelerate commercialization in 2026.